Literature DB >> 15766633

Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine.

Kamini L Ho Pian1, Harold J G M van Megen, Nick F Ramsey, René Mandl, Peter P van Rijk, H J Wynne, Herman G M Westenberg.   

Abstract

Functional imaging studies have pointed to a role of the orbitofrontal cortex (OFC), striatum and thalamus in the pathophysiology of obsessive-compulsive disorder (OCD). Effective treatment has been found to change brain activity within this circuitry. The aim of the present study was to explore possible differential effects of OCD responders and non-responders to drug treatment on the regional cerebral blood flow (rCBF). Measurements of rCBF were carried out in 15 out of 22 patients with OCD who completed an open-label trial with fluvoxamine. Patients were studied with 99mTc-HMPAO single photon emission computed tomography (SPECT) before and after 12 weeks of treatment. In addition, structural magnetic resonance imaging was obtained on all patients. Regions of interest comprised the OFC, caudate nucleus, putamen and thalamus. Seven patients responded to treatment. Levels of rCBF decreased significantly in the left caudate nucleus and the left and right putamen in both responders and non-responders to treatment. In responders, but not in non-responders, a significant decrease in rCBF was found in the right thalamus. Pre-treatment cerebellar and whole brain HMPAO uptake was significantly higher in responders to treatment compared with non-responders. We suggest that the thalamus plays a central role in the response to drug treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766633     DOI: 10.1016/j.pscychresns.2004.12.003

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  17 in total

1.  Caudate volume differences among treatment responders, non-responders and controls in children with obsessive-compulsive disorder.

Authors:  Edoardo F Q Vattimo; Vivian B Barros; Guaraci Requena; João R Sato; Daniel Fatori; Euripedes C Miguel; Roseli G Shavitt; Marcelo Q Hoexter; Marcelo C Batistuzzo
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-04-10       Impact factor: 4.785

Review 2.  The prefrontal cortex and OCD.

Authors:  Susanne E Ahmari; Scott L Rauch
Journal:  Neuropsychopharmacology       Date:  2021-08-16       Impact factor: 7.853

3.  MRI study of the cavum septum pellucidum in obsessive-compulsive disorder.

Authors:  Myong-Wuk Chon; Jung-Seok Choi; Do-Hyung Kang; Myung Hun Jung; Jun Soo Kwon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-10-25       Impact factor: 5.270

4.  Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder.

Authors:  S Saxena; E Gorbis; J O'Neill; S K Baker; M A Mandelkern; K M Maidment; S Chang; N Salamon; A L Brody; J M Schwartz; E D London
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

Review 5.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

6.  Altered brain activation in ventral frontal-striatal regions following a 16-week pharmacotherapy in unmedicated obsessive-compulsive disorder.

Authors:  Ji Yeon Han; Do-Hyung Kang; Bon-Mi Gu; Wi Hoon Jung; Jung-Seok Choi; Chi-Hoon Choi; Joon Hwan Jang; Jun Soo Kwon
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

7.  Defining functional brain networks underlying obsessive-compulsive disorder (OCD) using treatment-induced neuroimaging changes: a systematic review of the literature.

Authors:  Kelly R Bijanki; Yagna J Pathak; Ricardo A Najera; Eric A Storch; Wayne K Goodman; H Blair Simpson; Sameer A Sheth
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-04-27       Impact factor: 10.154

8.  The Effects of Psychopharmacologic and Therapeutic Approaches on Neuro-imaging in Obsessive-compulsive Disorder.

Authors:  Murad Atmaca
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

9.  Neuroimaging predictors of treatment response in anxiety disorders.

Authors:  Lisa M Shin; F Caroline Davis; Michael B Vanelzakker; Mary K Dahlgren; Stacey J Dubois
Journal:  Biol Mood Anxiety Disord       Date:  2013-08-02

10.  Management of obsessive-compulsive disorder with fluvoxamine extended release.

Authors:  Lídia Ordacgi; Mauro V Mendlowicz; Leonardo F Fontenelle
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.